neurology Archives

First Opinion By Bernard Zipprich

Will the shadow of Aduhelm cloud FDA’s decision-making on an ALS therapy?

The Pharmalot View By Ed Silverman

‘Precedents are important’: Aduhelm coverage restrictions could shape the future of accelerated approval

Health Tech By Katie Palmer

With pharma still struggling in Alzheimer’s, health tech companies want a swing

In the Lab By Meghana Keshavan

With new ‘brain-reading’ research, a once-tarnished scientist seeks redemption

D.C. Diagnosis By Nicholas Florko

Before Aduhelm, Billy Dunn was a superstar at the FDA

Video Chat By Gideon Gil

Virtual Event – ‘Augmented’: The future of brain-controlled prosthetic limbs

Special Report By Isabella Cueto

Jolting the brain’s circuits with electricity is moving from radical to almost mainstream therapy. Some crucial hurdles remain

Pharmalot By Ed Silverman

A looming decision on Medicare coverage for Biogen’s Alzheimer’s drug could shock state Medicaid programs

Biotech By Maaisha Osman

4 epilepsy-focused biotech companies to watch

Exclusive By Kate Sheridan

Flagship to launch a new startup focused on neurodegenerative conditions, including Parkinson’s

Biotech By Matthew Herper

Acadia drug meets endpoints for treating Rett syndrome, a rare neurological disease

Biotech By Damian Garde

Cortexyme bets a lower dose of its once-failed Alzheimer’s drug can work in another trial

The Pharmalot View By Ed Silverman

‘Remember her as the badass she was’: ALS patient who died should force Biogen, others to anticipate expanded access issues

Pharmalot By Ed Silverman and Damian Garde

Veterans Affairs declines to cover Biogen’s Alzheimer’s drug over effectiveness, safety concerns

Biotech By Joanne Silberner

Accelerated approval, the path used to greenlight Biogen Alzheimer’s drug, has a checkered track record, critics say

Pharmalot By Ed Silverman

Expert panel votes unanimously that Biogen Alzheimer’s drug doesn’t offer patient benefits

STAT Summit By Elizabeth Cooney

‘Aduhelm left room’: Lilly CEO eyes competition with Biogen Alzheimer’s drug

Pharmalot By Ed Silverman

Poll: Most neurologists and primary care doctors disagree with FDA’s approval of Alzheimer’s drug

Pharmalot By Ed Silverman

Will FDA quickly review a Lilly drug to alleviate cost concerns for Alzheimer’s treatments?

Health By Megan Molteni

A crucial, overlooked question on the new Alzheimer’s drug: When should patients stop taking it?

Pharmalot By Ed Silverman

Poll: Most Americans believe new Alzheimer’s drug is effective, but many are concerned with FDA process

Pharmalot By Ed Silverman

‘A litany of flaws’: Advocacy group urges HHS to boot FDA officials over Alzheimer’s drug approval

Health By Elizabeth Cooney

‘I’m just winging it’: Faced with confusing data on the new Alzheimer’s drug, doctors scramble to advise their patients

Biotech By Nicholas Florko

Advocates blast the FDA for not moving as fast on ALS as on Alzheimer’s

Biotech By Felice J. Freyer — Boston Globe

Most Read

An ALS therapy sets up a crucial test of the FDA’s independence

Scientists take key step toward unraveling the genetic roots of ALS in a pair of studies

In ‘chemo brain,’ researchers see clues to unravel long Covid’s brain fog

Strong new evidence suggests a virus triggers multiple sclerosis

New study revives a Mozart sonata as a potential epilepsy therapy

6 ways the FDA’s approval of Aduhelm does more harm than good

Long after the fire of a Covid-19 infection, mental and neurological effects can still smolder

Worries about accuracy of widely used dementia test prompt training requirement

All Coverage

Will the shadow of Aduhelm cloud FDA’s decision-making on an ALS therapy?

‘Precedents are important’: Aduhelm coverage restrictions could shape the future of accelerated approval

With pharma still struggling in Alzheimer’s, health tech companies want a swing

With new ‘brain-reading’ research, a once-tarnished scientist seeks redemption

Before Aduhelm, Billy Dunn was a superstar at the FDA

Virtual Event – ‘Augmented’: The future of brain-controlled prosthetic limbs

Jolting the brain’s circuits with electricity is moving from radical to almost mainstream therapy. Some crucial hurdles remain

A looming decision on Medicare coverage for Biogen’s Alzheimer’s drug could shock state Medicaid programs

4 epilepsy-focused biotech companies to watch

Flagship to launch a new startup focused on neurodegenerative conditions, including Parkinson’s

Acadia drug meets endpoints for treating Rett syndrome, a rare neurological disease

Cortexyme bets a lower dose of its once-failed Alzheimer’s drug can work in another trial

‘Remember her as the badass she was’: ALS patient who died should force Biogen, others to anticipate expanded access issues

Veterans Affairs declines to cover Biogen’s Alzheimer’s drug over effectiveness, safety concerns

Accelerated approval, the path used to greenlight Biogen Alzheimer’s drug, has a checkered track record, critics say

Expert panel votes unanimously that Biogen Alzheimer’s drug doesn’t offer patient benefits

‘Aduhelm left room’: Lilly CEO eyes competition with Biogen Alzheimer’s drug

Poll: Most neurologists and primary care doctors disagree with FDA’s approval of Alzheimer’s drug

Will FDA quickly review a Lilly drug to alleviate cost concerns for Alzheimer’s treatments?

A crucial, overlooked question on the new Alzheimer’s drug: When should patients stop taking it?

Poll: Most Americans believe new Alzheimer’s drug is effective, but many are concerned with FDA process

‘A litany of flaws’: Advocacy group urges HHS to boot FDA officials over Alzheimer’s drug approval

‘I’m just winging it’: Faced with confusing data on the new Alzheimer’s drug, doctors scramble to advise their patients

Advocates blast the FDA for not moving as fast on ALS as on Alzheimer’s

What’s next for the new Alzheimer’s drug? Lots of thorny issues ahead

Subscribe to STAT for $15 per month lorem ipsum